Abstract
The increase of cell surface sialic acid is a characteristic shared by many tumor types. A correlation between hypersialylation and immunoprotection has been observed, but few hypotheses have provided a mechanistic understanding of this immunosuppressive phenomenon. Here, we show that increasing sialylated glycans on cancer cells inhibits human natural killer (NK) cell activation through the recruitment of sialic acid–binding immunoglobulin-like lectin 7 (Siglec-7). Key to these findings was the use of glycopolymers end-functionalized with phospholipids, which enable the introduction of synthetically defined glycans onto cancer cell surfaces. Remodeling the sialylation status of cancer cells affected the susceptibility to NK cell cytotoxicity via Siglec-7 engagement in a variety of tumor types. These results support a model in which hypersialylation offers a selective advantage to tumor cells under pressure from NK immunosurveillance by increasing Siglec ligands. We also exploited this finding to protect allogeneic and xenogeneic primary cells from NK-mediated killing, suggesting the potential of Siglecs as therapeutic targets in cell transplant therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239–252 (2012).
Zamai, L. et al. NK cells and cancer. J. Immunol. 178, 4011–4016 (2007).
Lanier, L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495–502 (2008).
Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. & Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Waldhauer, I. & Steinle, A. NK cells and cancer immunosurveillance. Oncogene 27, 5932–5943 (2008).
Mamessier, E. et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121, 3609–3622 (2011).
Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734–738 (2002).
Fukuda, M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res. 56, 2237–2244 (1996).
Leivonen, M., Nordling, S., Lundin, J., von Boguslawski, K. & Haglund, C. STn and prognosis in breast cancer. Oncology 61, 299–305 (2001).
Dennis, J., Waller, C., Timpl, R. & Schirrmacher, V. Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. Nature 300, 274–276 (1982).
Fuster, M.M. & Esko, J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526–542 (2005).
Cohen, M. et al. Sialylation of 3-methylcholanthrene–induced fibrosarcoma determines antitumor immune responses during immunoediting. J. Immunol. 185, 5869–5878 (2010).
Van Rinsum, J., Smets, L.A., Van Rooy, H. & Van den Eijnden, D.H. Specific inhibition of human natural killer cell–mediated cytotoxicity by sialic acid and sialo-oligosaccharides. Int. J. Cancer 38, 915–922 (1986).
Yogeeswaran, G. et al. Correlation of glycosphingolipids and sialic acid in YAC-1 lymphoma variants with their sensitivity to natural killer-cell–mediated lysis. Int. J. Cancer 28, 517–526 (1981).
Ogata, S., Maimonis, P.J. & Itzkowitz, S.H. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res. 52, 4741–4746 (1992).
Crocker, P.R., Paulson, J.C. & Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7, 255–266 (2007).
Paulson, J.C., Macauley, M.S. & Kawasaki, N. Siglecs as sensors of self in innate and adaptive immune responses. Ann. NY Acad. Sci. 1253, 37–48 (2012).
Nicoll, G. et al. Identification and characterization of a novel siglec, Siglec-7, expressed by human natural killer cells and monocytes. J. Biol. Chem. 274, 34089–34095 (1999).
Ikehara, Y., Ikehara, S.K. & Paulson, J.C. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J. Biol. Chem. 279, 43117–43125 (2004).
Avril, T., Floyd, H., Lopez, F., Vivier, E. & Crocker, P.R. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J. Immunol. 173, 6841–6849 (2004).
Nath, D. et al. Macrophage–tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 98, 213–219 (1999).
Takamiya, R., Ohtsubo, K., Takamatsu, S., Taniguchi, N. & Angata, T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology 23, 178–187 (2013).
Belisle, J.A. et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol. Cancer 9, 118 (2010).
Kiessling, L.L. & Splain, R.A. Chemical approaches to glycobiology. Annu. Rev. Biochem. 79, 619–653 (2010).
Collins, B.E. & Paulson, J.C. Cell surface biology mediated by low affinity multivalent protein–glycan interactions. Curr. Opin. Chem. Biol. 8, 617–625 (2004).
Brown, J.M. et al. A sulfated carbohydrate epitope inhibits axon regeneration after injury. Proc. Natl. Acad. Sci. USA 109, 4768–4773 (2012).
Courtney, A.H., Puffer, E.B., Pontrello, J.K., Yang, Z.-Q. & Kiessling, L.L. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc. Natl. Acad. Sci. USA 106, 2500–2505 (2009).
Collins, B.E. et al. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J. Immunol. 177, 2994–3003 (2006).
Rabuka, D., Forstner, M.B., Groves, J.T. & Bertozzi, C.R. Noncovalent cell surface engineering: incorporation of bioactive synthetic glycopolymers into cellular membranes. J. Am. Chem. Soc. 130, 5947–5953 (2008).
Belardi, B., O'Donoghue, G.P., Smith, A.W., Groves, J.T. & Bertozzi, C.R. Investigating cell surface galectin-mediated cross-linking on glycoengineered cells. J. Am. Chem. Soc. 134, 9549–9552 (2012).
Hudak, J.E., Yu, H.H. & Bertozzi, C.R. Protein glycoengineering enabled by the versatile synthesis of aminooxy glycans and the genetically encoded aldehyde tag. J. Am. Chem. Soc. 133, 16127–16135 (2011).
Nicoll, G. et al. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via Siglec-7–dependent and –independent mechanisms. Eur. J. Immunol. 33, 1642–1648 (2003).
Blixt, O., Collins, B.E., van den Nieuwenhof, I.M., Crocker, P.R. & Paulson, J.C. Sialoside specificity of the Siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J. Biol. Chem. 278, 31007–31019 (2003).
Attrill, H. et al. Siglec-7 undergoes a major conformational change when complexed with the α(2,8)-disialylganglioside GT1b. J. Biol. Chem. 281, 32774–32783 (2006).
Daëron, M., Jaeger, S., Du Pasquier, L. & Vivier, E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol. Rev. 224, 11–43 (2008).
Falco, M. et al. Identification and molecular cloning of P75/Airm1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells. J. Exp. Med. 190, 793–802 (1999).
Maki, G., Klingemann, H.G., Martinson, J.A. & Tam, Y.K. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J. Hematother. Stem Cell Res. 10, 369–383 (2001).
Terme, M., Ullrich, E., Delahaye, N.F., Chaput, N. & Zitvogel, L. Natural killer cell–directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9, 486–494 (2008).
Dall'Ozzo, S. et al. Rituximab-dependent cytotoxicity by natural killer cells influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64, 4664–4669 (2004).
Triulzi, C. et al. Antibody-dependent natural killer cell–mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res. 70, 7431–7441 (2010).
van der Touw, W. & Bromberg, J.S. Natural killer cells and the immune response in solid organ transplantation. Am. J. Transplant. 10, 1354–1358 (2010).
Murphy, W.J., Vinay, K. & Bennett, M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J. Exp. Med. 165, 1212–1217 (1987).
Murphy, W.J., Koh, C.Y., Raziuddin, A., Bennett, M. & Longo, D.L. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol. Rev. 181, 279–289 (2001).
Li, S., Waer, M. & Billiau, A.D. Xenotransplantation: role of natural immunity. Transpl. Immunol. 21, 70–74 (2009).
Forte, P., Lilienfeld, B.G., Baumann, B.C. & Seebach, J.D. Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J. Immunol. 175, 5463–5470 (2005).
Marth, J.D. & Grewal, P.K. Mammalian glycosylation in immunity. Nat. Rev. Immunol. 8, 874–887 (2008).
Avril, T., North, S.J., Haslam, S.M., Willison, H.J. & Crocker, P.R. Probing the cis interactions of the inhibitory receptor Siglec-7 with α2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of α2,8-sialyltransferase gene expression. J. Leukoc. Biol. 80, 787–796 (2006).
Kawasaki, Y. et al. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells. Glycobiology 20, 1373–1379 (2010).
Liang, Y.-J. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc. Natl. Acad. Sci. USA 110, 4968–4973 (2013).
Rabuka, D. et al. Hierarchical assembly of model cell surfaces: synthesis of mucin mimetic polymers and their display on supported bilayers. J. Am. Chem. Soc. 129, 5462–5471 (2007).
Leonard, J.P. et al. Epratuzumab, a humanized Anti-CD22 antibody, in aggressive non-Hodgkin's Lymphoma phase I/II clinical trial results. Clin. Cancer Res. 10, 5327–5334 (2004).
Ménard, S., Pupa, S.M., Campiglio, M. & Tagliabue, E. Biologic and therapeutic role of HER2 in cancer. Oncogene 22, 6570–6578 (2003).
Sommaggio, R., Pérez-Cruz, M. & Costa, C. Cellular studies for in vitro modeling of xenogeneic immune responses. Methods Mol. Biol. 885, 91–103 (2012).
Bryceson, Y.T., March, M.E., Ljunggren, H.-G. & Long, E.O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107, 159–166 (2006).
Godal, R. et al. Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. Blood 107, 3205–3211 (2006).
Bryceson, Y.T. et al. Functional analysis of human NK cells by flow cytometry. Methods Mol. Biol. 612, 335–352 (2010).
Aalto, K. et al. Siglec-9 Is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. Blood 118, 3725–3733 (2011).
Naviaux, R.K., Costanzi, E., Haas, M. & Verma, I.M. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70, 5701–5705 (1996).
Acknowledgements
We would like to thank J. Paulson (Scripps Research Institute) for the gift of plasmids encoding Siglec-7 and Siglec-9; M. Boyce (Duke University) for the gift of pMSCV retroviral plasmids and advice; D. Raulet, M. Ardolino, A. Iannello, P. Drake and C. Hudak for advice and expertise; and B. Belardi and D. Rabuka for helpful discussion and manuscript critique. This work was funded by a grant from the US National Institutes of Health (R01 GM59907). J.E.H. was supported by a predoctoral fellowship from the US National Science Foundation. S.M.C. was supported by a postdoctoral fellowship from the US National Institutes of Health (F32DK095521).
Author information
Authors and Affiliations
Contributions
J.E.H. synthesized compounds, designed and performed the experiments, analyzed the data and prepared the manuscript. S.M.C. performed the experiments, analyzed the data, and revised the manuscript. C.R.B. directed the study and revised the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Figures 1–16 and Supplementary Notes 1 and 2. (PDF 1836 kb)
Rights and permissions
About this article
Cite this article
Hudak, J., Canham, S. & Bertozzi, C. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol 10, 69–75 (2014). https://doi.org/10.1038/nchembio.1388
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1388
This article is cited by
-
Immunoengineering can overcome the glycocalyx armour of cancer cells
Nature Materials (2024)
-
Polymeric biomaterial-inspired cell surface modulation for the development of novel anticancer therapeutics
Biomaterials Research (2023)
-
Chemoenzymatic synthesis of genetically-encoded multivalent liquid N-glycan arrays
Nature Communications (2023)
-
Activation of immune signals during organ transplantation
Signal Transduction and Targeted Therapy (2023)
-
Site-selected in situ polymerization for living cell surface engineering
Nature Communications (2023)